Dr. Sulaiman Al Habib Medical Services Group announces its Interim Financial results for the Period Ending on 2025-09-30 ( Nine Months )
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 3,463.34 | 2,976.56 | 16.353 | 3,384.33 | 2.334 |
| Gross Profit (Loss) | 1,049.93 | 992.1 | 5.829 | 1,065.98 | -1.505 |
| Operational Profit (Loss) | 665.71 | 624.38 | 6.619 | 644.87 | 3.231 |
| Net profit (Loss) | 602.28 | 595.54 | 1.131 | 591.02 | 1.905 |
| Total Comprehensive Income | 605.93 | 600.48 | 0.907 | 595.78 | 1.703 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Sales/Revenue | 10,005.45 | 8,071.59 | 23.958 |
| Gross Profit (Loss) | 3,144.22 | 2,747.45 | 14.441 |
| Operational Profit (Loss) | 1,936.5 | 1,732.13 | 11.798 |
| Net profit (Loss) | 1,750.31 | 1,701.52 | 2.867 |
| Total Comprehensive Income | 1,748.21 | 1,726.62 | 1.25 |
| Total Shareholders Equity (after Deducting Minority Equity) | 7,684.35 | 6,990.61 | 9.923 |
| Profit (Loss) per Share | 5 | 4.86 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | Revenues: for Q3–2025, increased by 16.35%, reaching SAR 3,463.34 million, compared to SAR 2,976.56 million in the same quarter of the previous year, representing an increase of SAR 486.78 million. This growth was mainly driven by both hospitals and pharmacies segments, supported by higher patient volumes and higher occupancy rates.
As part of its ongoing growth strategy, the Group launched several new hospitals across key regions. In 2024, operations commenced at Al-Fayhaa Hospital (Al-Fayhaa District, Jeddah), Shamal Al Riyadh Hospital (Al-Sahafa District, Riyadh), and the Women's Health Hospital (Rahmaniyah District, Riyadh). These expansions continued in 2025 with the operational openings of Al-Hamra Hospital (Al-Hamra District, Riyadh), Al-Kharj Hospital (Al-Jawhara District, Al-Kharj), and Al Muhammadiyah Hospital (Al Muhammadiyah District, Jeddah). The recently commissioned hospitals are ramping up operations, and their revenue generation is anticipated to rise progressively to reach the optimal operating capacity. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | EBITDA for Q3–2025 increased by 15.14%, reaching SAR 889.77 million as compared to SAR 772.75 million in the same quarter of the last year. EBITDA margin remained stable at 25.69%.
Net income increased by 1.13% during Q3–2025, reaching SAR 602.28 million compared to SAR 595.54 million in the same quarter of the previous year. This increase was primarily driven by higher revenues, partially offset by fixed operating costs related to newly launched hospitals that are still in their early ramp-up stages and are expected to progressively reach optimal operational capacity. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | Revenue growth of 2.33% during Q3–2025 as compared to the Q2–2025, was driven primarily by the growth in the number of patients of the hospitals and pharmacies segments. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | Net income attributable to the company’s shareholders increased by 1.91% in Q3–2025 compared to the Q2–2025, supported by the increase in revenues. |
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | Revenues: for the nine-month period ended 30 September 2025, revenues grew by 23.96%, reaching SAR 10,005.45 million, compared to SAR 8,071.59 million in the same period of the previous year, representing an increase of SAR 1,933.86 million. This growth was primarily driven by both the hospitals and pharmacies segments, supported by higher patient volumes and higher occupancy rates. As part of its ongoing growth strategy, the Group launched several new hospitals across key regions. In 2024, operations commenced at Al-Fayhaa Hospital (Al-Fayhaa District, Jeddah), Shamal Al Riyadh Hospital (Al-Sahafa District, Riyadh), and the Women’s Health Hospital (Rahmaniyah District, Riyadh). This expansion continued in 2025 with the operational openings of Al-Hamra Hospital (Al-Hamra District, Riyadh), Al-Kharj Hospital (Al-Jawhara District, Al-Kharj), and Al Muhammadiyah Hospital (Al Muhammadiyah District, Jeddah). The recently commissioned hospitals are ramping up operations, and their revenue generation is expected to increase progressively until they reach optimal operating capacity. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | EBITDA for the nine-month period ended 30th September 2025 increased by 19.99%, reaching SAR 2,564.07 million as compared to SAR 2,136.98 million in the same period of the last year. EBITDA margin reached 25.63%.
Net Income increased by 2.87% for the nine-month period ended 30th September 2025, reaching SAR 1,750.31 million, compared to SAR 1,701.52 million in the same period of the previous year. This increase was primarily driven by higher revenues, partially offset by fixed operating costs related to newly launched hospitals that are still in their early ramp-up stages and are expected to progressively reach optimal operational capacity. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | na |
| Reclassification of Comparison Items | na |
| Additional Information | na |
| Attached Documents |  |
